Elevance Health, Inc. $ELV Shares Bought by denkapparat Operations GmbH

denkapparat Operations GmbH increased its position in Elevance Health, Inc. (NYSE:ELV) by 78.0% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 3,108 shares of the company’s stock after acquiring an additional 1,362 shares during the period. denkapparat Operations GmbH’s holdings in Elevance Health were worth $1,202,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Field & Main Bank grew its holdings in Elevance Health by 1.3% during the second quarter. Field & Main Bank now owns 1,883 shares of the company’s stock worth $728,000 after acquiring an additional 25 shares during the period. Tranquilli Financial Advisor LLC lifted its holdings in Elevance Health by 1.3% in the 2nd quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company’s stock valued at $805,000 after acquiring an additional 26 shares during the last quarter. WealthCollab LLC lifted its holdings in Elevance Health by 42.2% in the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after acquiring an additional 27 shares during the last quarter. Signet Financial Management LLC boosted its position in shares of Elevance Health by 3.5% during the 1st quarter. Signet Financial Management LLC now owns 837 shares of the company’s stock valued at $245,000 after purchasing an additional 28 shares in the last quarter. Finally, Sapient Capital LLC boosted its position in shares of Elevance Health by 1.2% during the 1st quarter. Sapient Capital LLC now owns 2,612 shares of the company’s stock valued at $765,000 after purchasing an additional 31 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Insiders Place Their Bets

In other Elevance Health news, Director Robert Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ELV shares. Robert W. Baird boosted their target price on shares of Elevance Health from $331.00 to $393.00 and gave the stock a “neutral” rating in a report on Thursday, July 16th. Evercore restated a “hold” rating on shares of Elevance Health in a report on Tuesday, May 19th. Morgan Stanley upped their price target on Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a report on Thursday, June 4th. Mizuho increased their price objective on Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $395.00 price objective on shares of Elevance Health in a research note on Thursday, July 16th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $440.90.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $415.05 on Friday. The company’s fifty day moving average is $396.48 and its two-hundred day moving average is $364.27. The company has a market cap of $90.01 billion, a P/E ratio of 18.45, a price-to-earnings-growth ratio of 2.11 and a beta of 0.69. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $436.24. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, topping the consensus estimate of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The business had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. During the same quarter last year, the firm posted $8.84 earnings per share. Elevance Health’s revenue was up .8% compared to the same quarter last year. Equities analysts expect that Elevance Health, Inc. will post 27.18 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.